


FORM PTO-1449



**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT**
(use several sheets if necessary)

SERIAL NO.

09/938,160

CASE NO.

P-191

FILING DATE

AUGUST 23, 2001

GROUP ART UNIT

NOT YET ASSIGNED

APPLICANT(S): WHITEHEAD ET AL.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
W	A1	3,031,450	4/24/62	Fischer et al.		
	A2	3,161,654	12/15/64	Shen		
	A3	3,312,730	4/4/67	Winter et al.		
	A4	3,322,755	5/30/67	Roch et al.		
	A5	3,325,358	6/13/67	Winter et al.		
	A6	3,532,752	10/6/70	Shen		
	A7	3,642,785	2/15/72	Shen et al.		
	A8	3,647,858	3/7/72	Hinkley et al.		
	A9	3,654,349	4/4/72	Shen et al.		
	A10	3,692,651	9/19/72	Sletzing et al.		
	A11	3,692,825	9/19/72	Conn		
	A12	3,737,455	6/5/73	Shen et al.		
	A13	3,851,063	11/26/74	Shen et al.		

RECEIVED
OCT 16 2001
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
W	A14	EP 0 293 063 B1	3/18/92	EPO		
	A15	EP 0 347 146 B1	9/1/93	EPO		
	A16	EP 0 349 239 A2	1/3/90	EPO		
	A17	EP 0 352 960 B1	10/26/94	EPO		
	A18	EP 0 351 058 B1	6/2/93	EPO		


EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
W	A19	Ahmad F. et al., IL-3 ad IL-4 Activate Cyclic Nucleotide Phosphodiesterases 3 (PDE3) and 4 (PDE4) by Different Mechanisms in FDCP2 Myeloid Cells, J. Immunology Vol. 162, Part 8, pp. 4864-4875 (Apr 15 1999).
W	A20	Boven LA et al., Macrophage inflammatory protein-1 alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions, Clin. Exp. Immunol. 2000 Nov.; 122(2): 257-63 (Abstract Only).
W	A21	Cooper N. et al., A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo, British Journal of Pharmacology (1999) 126, pp. 1863-1871.
W	A22	Czirjak L. et al., Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis, Clin Rheumatology 1999; 18(5), pp. 357-363 (Abstract Only).
W	A23	Danahay H. et al., PDE4 inhibition and a corticosteroid in chronically antigen exposed conscious guinea-pigs, Clinical and Experimental Allergy, 1998, Vol. 28, pp. 513-522.
W	A24	Duggan, D.E. et al., Identification of the Biologically Active Form of Sulindac, J. Pharm. & Exper. Therap., Vol. 201, No. 1, pp.8-13 (1977).

EXAMINER

DATE CONSIDERED

6/5/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449	SERIAL NO. 09/938,160	CASE NO. P-191
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
	APPLICANT(S): WHITEHEAD ET AL.	

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
[Signature]	A25	3,860,636	11/14/75	Shen et al.		
	A26	4,402,979	9/6/83	Shen et al.		
	A27	4,307,114	12/22/81	Dvornik et al.		
	A28	4,423,074	12/27/83	Dvornik et al.		
	A29	4,423,075	12/27/83	Dvornik et al.		
	A30	4,880,810	11/14/89	Lowe, III		
	A31	4,885,301	12/5/89	Coates		
	A32	5,298,525	3/29/94	Yoon et al.		
	A33	5,401,774	3/28/95	Pamukcu et al.		
	A34	5,470,873	11/28/95	Yoon		
	A35	5,488,055	1/30/96	Kumar et al.		
	A36	5,527,896	6/18/96	Wigler et al.		
	A37	5,602,019	2/11/97	Beavo et al.		

RECEIVED

OCT 16 2001

TECH CENTER 1600/2900


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
[Signature]	A38	EP 0 395 328 A2	10/31/90	EPO		
	A39	EP 0 428 268 A2	5/22/91	EPO		
	A40	EP 0 463 756 A1	1/2/92	EPO		
	A41	EP 0 526 004 A1	2/3/93	EPO		
	A42	EP 0 722 943 A1	1/8/96	EPO		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
[Signature]	A43	Gantner F. et al., Characterization of the Phosphodiesterase (PDE) Pattern of in Vitro-Generated Human Dendritic Cells (DC) and the Influence of PDE Inhibitors on DC Function, Pulmonary Pharmacology & Therapeutics (1999) 12, pp. 377-386.
[Signature]	A44	Gantner F. et al., In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor- α release by PDE inhibitors, British Journal of Pharmacology (1997) 121, pp. 221-231.
[Signature]	A45	Gehrman J. et al., Amyloid precursor protein (APP) expression in multiple sclerosis lesions, Glia 1995 Oct;15(2), pp. 141-151 (Abstract Only).
[Signature]	A46	Germain N. et al., Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs, Eur. Respir. J. 1998;12, pp. 1334-1339.
[Signature]	A47	Giembyez, M.A., Phosphodiesterase 4 Inhibitors and the Treatment of Asthma, Drugs 2000 Feb; 59(2), pp. 193-212.
	A48	Gonzaga, R.A.F. et al., The Lancet, 3/30/85, p. 751.

EXAMINER [Signature]	DATE CONSIDERED 6/5/01
----------------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		SERIAL NO.	CASE NO.
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		09/938,160	P-191
		FILING DATE	GROUP ART UNIT
		AUGUST 23, 2001	NOT YET ASSIGNED
		APPLICANT(S): WHITEHEAD ET AL.	

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
J	A49	5,602,171	2/11/97	Tang et al.		
	A50	5,614,530	3/25/97	Kumar et al.		
	A51	5,614,627	3/25/97	Takase et al.		
	A52	5,708,022	1/13/98	Bastos et al.		
	A53	5,776,752	7/7/98	Beavo et al.		
	A54	5,789,553	8/4/98	Beavo et al.		
	A55	5,798,374	8/25/98	Tang et al.		
	A56	5,800,987	9/1/98	Beavo et al.		
	A57	5,852,035	12/22/98	Pamukcu et al.		
	A58	5,858,694	1/12/99	Piazza et al.		
	A59	5,861,396	1/19/99	Niewöhner et al.		
A60	5,874,440	2/23/99	Pamukcu et al.			
A61	5,883,110	3/16/99	Tang et al.			







RECEIVED

OCT 16 2001

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
J	A62	EP 0 722 944 A1	1/8/96	EPO	
	A63	EP 1 074 258 A3	4/18/01	EPO	
	A64	GB 807,826	1/21/59	United Kingdom	
	A65	GB 2 063 249 A	6/3/81	United Kingdom	
	A66	HEI 8-311035	11/26/96	Japan	

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
	A67	Hammermann, R. et al., Phosphodiesterase Inhibitors and Forskolin Up-regulate Arginase Activity in Rabbit Alveolar Macrophages, Pulmonary Pharmacology and Therapeutics 2000; Vol. 13, No. 3, pp. 141-147.
	A68	He W. et al., Novel Cyclic Compounds as Potent Phosphodiesterase 4 Inhibitors, J. Med. Chem., Vol. 41, Part 22, pp. 4216-4223 (Oct 22 1998)
	A69	Hollander AP et al., Expression of hypoxia-inducible factor 1 alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint, Arthritis Rheum. 2001 Jul; 44(7): 1540-4 (Abstract Only).
	A70	Imahashi K. et al., Type IV Phosphodiesterase Inhibitor Suppresses Insulin-Dependent Myocardial Glucose Uptake, Clin Exp Pharmacol Physiol 2001 Apr;28(4), pp. 290-291 (Abstract Only)
	A71	Ishikawa O. et al., Macrophage infiltration in the skin of patients with systemic sclerosis, J. Rheumatology 1992 Aug; 19(8), pp. 1202-1206 (Abstract Only).
	A72	Kapur S. et al., Expression of Nitric Oxide Synthase in Skeletal Muscle, Diabetes, Vol. 46, Nov. 1997, pp. 1691-1700.

EXAMINER	DATE CONSIDERED
	6/8/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT**
(use several sheets if necessary)

SERIAL NO.

09/938,160

CASE NO.

P-191

FILING DATE

AUGUST 23, 2001

GROUP ART UNIT

NOT YET ASSIGNED

APPLICANT(S): WHITEHEAD ET AL.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A73	5,885,834	3/23/99	Epstein		
	A74	5,902,827	5/11/99	Pamukcu et al.		
	A75	5,922,595	7/13/99	Fisher et al.		
	A76	5,942,520	8/24/99	Pamukcu et al.		
	A77	5,948,911	9/7/99	Pamukcu et al.		
	A78	5,958,982	9/28/99	Pamukcu et al.		
	A79	5,990,117	11/23/99	Pamukcu et al.		
	A80	5,998,463	12/7/99	Hulin et al.		
	A81	6,008,215	12/28/99	Flockerzi		
	A82	6,015,677	1/18/00	Beavo et al.		
	A83	6,034,099	3/7/00	Pamukcu et al.		
	A84	6,037,345	3/14/00	Pamukcu et al.		
	A85	6,046,199	4/4/00	Pamukcu et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
	A86	SHO 61-106521	5/24/86	Japan		
	A87	WO 01/04099 A1	1/18/01	PCT		
	A88	WO 00/12501	3/9/00	PCT		
	A89	WO 00/26201	5/11/00	PCT		
	A90	WO 00/23091	4/27/00	PCT		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
	A91	Kelly J. et al., Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors, British Journal of Pharmacology (1998) 124, PP. 129-140.
	A92	Kelly J. et al., Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [³ H]R(-)-rolipram binding by selective inhibitors, Biochem. J. (1996) 318, pp. 425-436.
	A93	Kumar A. et al., Analgesic and anti-inflammatory effects of phosphodiesterase inhibitors, Indian J Exp Biol 2000 Jan;38(1), pp. 26-30 (Abstract Only)
	A94	Lee MS et al., A comparative immunohistochemical study of lichen planus and discoid lupus erythematosus, Australas J. Dermatol. 1996 Nov.; 37(4): 188-92 (Abstract Only).
	A95	McPherson M.A. et al., A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein, FEBS Letters 464 (1999), pp. 48-52.
	A96	Mery P.F. et al., Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes, Mol. Pharmacology 1995 Jul;48(1), pp. 121-130 (Abstract Only)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT**
(use several sheets if necessary)

SERIAL NO.

09/938,160

CASE NO.

P-191

FILING DATE

AUGUST 23, 2001

GROUP ART UNIT

NOT YET ASSIGNED

APPLICANT(S): WHITEHEAD ET AL.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
✓	A97	6,046,206	4/4/00	Pamukcu et al.		
	A98	6,046,216	4/4/00	Piazza et al.		
	A99	6,060,477	5/9/00	Piazza et al.		
	A100	6,066,634	5/23/00	Sperl et al.		
	A101	6,069,240	5/30/00	Wigler et al.		
	A102	6,071,934	6/6/00	Sperl et al.		
	A103	6,077,842	6/20/00	Pamukcu et al.		
	A104	6,080,540	6/27/00	Wigler et al.		
	A105	6,080,742	6/27/00	Germann et al.		
	A106	6,080,772	6/27/00	Tang et al.		
	A107	6,100,025	8/8/00	Wigler et al.		
	A108	6,107,295	8/22/00	Rochus et al.		
	A109	6,124,303	9/26/00	Pamukcu et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
✓	A110	WO 00/26208	5/11/00	PCT		
	A111	WO 00/27861	5/18/00	PCT		
	A112	WO 00/42017	7/20/00	PCT		
	A113	WO 00/42018	7/20/00	PCT		
	A114	WO 00/42019	7/20/00	PCT		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
✓	A115	Méry, Pierre-François et al., EHNA as an Inhibitor of PDE2: A Pharmacological and Biochemical Study in Cardiac Myocytes, Phosphodiesterase Inhibitors (1996), pp. 81-88.
✓	A116	Michie, A.M. et al., Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram, Cell Signal 1996 Feb;8(2), pp. 97-110.
✓	A117	Niebauer J. et al., Local L-Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis, Circulation 1999;100, pp. 1830-1835.
✓	A118	Odoux C. et al., Endothelin-1 secretion by alveolar macrophages in systemic sclerosis, Am. J. Respir. Crit. Care Med. 1997;Nov;156(5), pp. 1429-1435 (Abstract Only).
✓	A119	Ostensen M. et al., Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus, Lupus (2001) 10, pp. 135-139.
✓	A120	Piazza G.A. et al., Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis, Cancer Research 55, Jul 15 1995, pp. 3110-3116.

EXAMINER

DATE CONSIDERED

6/5/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	SERIAL NO. 09/938,160	CASE NO. P-191
	FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
	APPLICANT(S): WHITEHEAD ET AL.	
	(use several sheets if necessary)	

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/SUBCLASS	FILING DATE
Y	A121 6,133,271	10/17/00	Pamukcu et al.		
	A122 6,143,746	11/7/00	Daugan et al.		
	A123 6,143,759	11/7/00	Flockerzi		
	A124 6,143,765	11/7/00	Tang et al.		
	A125 6,143,777	11/7/00	Jonas et al.		
	A126 6,169,090	1/2/01	Dyke et al.		
	A127 6,174,884	1/16/01	Haning et al.		
	A128 6,187,779	2/13/01	Pamukcu et al.		
	A129 6,200,771	3/13/01	Liu et al.		
	A130 6,200,980	3/13/01	Piazza et al.		
	A131 6,207,666	3/27/01	Piazza et al.		
	A132 6,211,177	4/3/01	Sperl et al.		
	A133 6,211,220	4/3/01	Pamukcu et al.		


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/SUBCLASS	TRANSLATION YES	TRANSLATION NO
Y	A134 WO 00/42034	7/20/00	PCT			
	A135 WO 00/59890	10/12/00	PCT			
	A136 WO 00/64424	11/2/00	PCT			
	A137 WO 99/65880	11/23/99	PCT			
	A138 WO 98/19679A1	5/14/98	PCT (Claims Only)			

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
Y	A139 Reis E. et al., Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice, PNAS 97(23): pp. 12764-12769. 1999
Y	A140 Rice P.L. et al., Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites, Cancer Research 2001, Feb 15;61(4), pp. 1541-1547 (Abstract Only).
Y	A141 Soh, Jae-Won et al., Cyclic GMP Mediates Apoptosis Induced by Sulindac Derivatives via Activation of c-Jun NH ₂ -Terminal Kinase 1, Clinical Cancer Research Vol. 6, pp. 4136-4141, October 2000.
Y	A142 Soh, Jae-Won et al., Protein Kinase G Activates the JNK1 Pathway via Phosphorylation of MEKK1, The Journal of Biological Chemistry, Vol. 276, No. 19, pp. 16406-16410 (2001).
Y	A143 Thompson, W.J. et al., Exisulind Induction of Apoptosis Involves Guanosine 3',5'-Cyclic Monophosphate Phosphodiesterase Inhibition, Protein Kinase G Activation, and Attenuated β -Catenin, Cancer Research 60, pp. 3338-3342, July 1, 2000.
Y	A144 Tien, Xiao-Ying, et al., Activation of the Cystic Fibrosis Transmembrane Conductance Regulator by cGMP in the Human Colonic Cancer Cell Line, Caco-2, The Journal of Biological Chemistry, Vol. 269, No. 1, pp. 51-54 (1994).

EXAMINER	DATE CONSIDERED
	6/5/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449	SERIAL NO. 09/938,160	CASE NO. P-191
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
	APPLICANT(S): WHITEHEAD ET AL.	

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
[Signature]	A145	6,232,312	5/15/01	Pamukcu et al.	
	A146	6,235,742	5/22/01	Bell et al.	
	A147	6,235,776	5/22/01	Pamukcu et al.	
	A148	6,235,782	5/22/01	Pamukcu et al.	
	A149	6,239,136	5/29/01	Pamukcu et al.	
	A150	6,251,904	6/26/01	Bunnage et al.	
	A151	6,255,303	7/3/01	Sterk et al.	
	A152	6,255,456	7/3/01	Fisher et al.	
	A153	6,258,833	7/10/01	Martins et al.	
	A154	6,268,372	7/31/01	Pamukcu et al.	

RECEIVED

OCT 16 2001

TECH CENTER 1600/2000

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
[Signature]	A155	WO 98/17668	4/30/98	PCT	
	A156	WO 98/14448	4/9/98	PCT	
	A157	WO 98/06722	2/19/98	PCT	
	A158	WO 97/24334	7/10/97	PCT	
	A159	WO 97/03985	2/6/97	PCT	

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
[Signature]	A160 Tsukahara T et al., Cytophagic histiocytic panniculitis in systemic lupus erythematosus, <i>Hiroshima J. Med. Sci.</i> , 1995 Mar; 44(1): 13-6 (Abstract Only).
	A161 Waddel W. R. et al., Sulindac for Polyposis of the Colon, <i>The American Journal of Surgery</i> , Vol. 157, Jan. 1989, pp. 175-179.
	A162 Waddel W. R. et al., Sulindac for Polyposis of the Colon, <i>Journal of Surgical Oncology</i> , 24: pp. 83-87 (1983).
	A163 Weyand CM and Goronzy JJ, HLA polymorphisms and T cells in rheumatoid arthritis, <i>Int. Rev. Immunol.</i> 1999; 19(1-2):37-39 (Abstract Only).
	A164 Wilder R.L. et al., Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus?, <i>Ann. NY Acad. Sci</i> 1999 June 22;876, pp. 14-31 (Abstract Only).

EXAMINER [Signature]	DATE CONSIDERED 6/5/08
----------------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

SERIAL NO.

09/938,160

CASE NO.

P-191

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION STATEMENT
(use several sheets if necessary)

FILING DATE
AUGUST 23, 2001

GROUP ART UNIT
NOT YET ASSIGNED

APPLICANT(S): WHITEHEAD ET AL.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A1	3,031,450	4/24/62	Fischer et al.		
	A2	3,161,654	12/15/64	Shen		
	A3	3,312,730	4/4/67	Winter et al.		
	A4	3,322,755	5/30/67	Roch et al.		
	A5	3,325,358	6/13/67	Winter et al.		
	A6	3,532,752	10/6/70	Shen		
	A7	3,642,785	2/15/72	Shen et al.		
	A8	3,647,858	3/7/72	Hinkley et al.		
	A9	3,654,349	4/4/72	Shen et al.		
	A10	3,692,651	9/19/72	Slettinger et al.		
	A11	3,692,825	9/19/72	Conn		
	A12	3,737,455	6/5/73	Shen et al.		
	A13	3,851,063	11/26/74	Shen et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
	A14	EP 0 293 063 B1	3/18/92	EPO		
	A15	EP 0 347 146 B1	9/1/93	EPO		
	A16	EP 0 349 239 A2	1/3/90	EPO		
	A17	EP 0 352 960 B1	10/26/94	EPO		
	A18	EP 0 351 058 B1	6/2/93	EPO		

EXAMINER
INITIAL

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	A19	Ahmad F. et al., IL-3 ad IL-4 Activate Cyclic Nucleotide Phosphodiesterases 3 (PDE3) and 4 (PDE4) by Different Mechanisms in FDCP2 Myeloid Cells, J. Immunology Vol. 162, Part 8, pp. 4864-4876 (Apr 15 1999).
	A20	Boven LA et al., Macrophage inflammatory protein-1 alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions; Clin. Exp. Immunol. 2000 Nov.; 122(2): 257-63 (Abstract Only).
	A21	Cooper N. et al., A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro, and eosinophil trafficking in vivo, British Journal of Pharmacology (1999) 126, pp. 1863-1871.
	A22	Czirjak L. et al., Investigation of the alveolar macrophages and T lymphocytes in 15 patients with systemic sclerosis, Clin Rheumatology 1999; 18(5), pp. 357-363 (Abstract Only).
	A23	Danahay H. et al., PDE4 inhibition and a corticosteroid in chronically antigen exposed conscious guinea-pigs, Clinical and Experimental Allergy, 1998, Vol. 28, pp. 513-522.
	A24	Duggan, D.E. et al., Identification of the Biologically Active Form of Sulindac, J. Pharm. & Exper. Therap., Vol. 201, No. 1, pp.8-13 (1977).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. 09/938,160	CASE NO. P-191
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
APPLICANT(S): WHITEHEAD ET AL.		

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A25	3,860,636	11/14/75	Shen et al.	
	A26	4,402,979	9/6/83	Shen et al.	
	A27	4,307,114	12/22/81	Dvornik et al.	
	A28	4,423,074	12/27/83	Dvornik et al.	
	A29	4,423,075	12/27/83	Dvornik et al.	
	A30	4,880,810	11/14/89	Lowe, III	
	A31	4,885,301	12/5/89	Coates	
	A32	5,298,525	3/29/94	Yoon et al.	
	A33	5,401,774	3/28/95	Pamukcu et al.	
	A34	5,470,873	11/28/95	Yoon	
	A35	5,488,055	1/30/96	Kumar et al.	
	A36	5,527,896	6/18/96	Wigler et al.	
	A37	5,602,019	2/11/97	Beavo et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
	A38	EP 0 395 328 A2	10/31/90	EPO	
	A39	EP 0 428 268 A2	5/22/91	EPO	
	A40	EP 0 463 756 A1	1/2/92	EPO	
	A41	EP 0 526 004 A1	2/3/93	EPO	
	A42	EP 0 722 943 A1	1/8/96	EPO	US 5,866,571

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
	A43 Gantner F. et al., Characterization of the Phosphodiesterase (PDE) Pattern of in Vitro-Generated Human Dendritic Cells (DC) and the Influence of PDE Inhibitors on DC Function, Pulmonary Pharmacology & Therapeutics (1999) 12; pp. 377-386.
	A44 Gantner F. et al., In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor- α release by PDE inhibitors, British Journal of Pharmacology (1997) 121, pp. 221-231.
	A45 Gehrmann J. et al., Amyloid precursor protein (APP) expression in multiple sclerosis lesions, Glia 1995 Oct;15(2), pp. 141-151 (Abstract Only).
	A46 Germain N. et al., Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs, Eur. Respir. J. 1998;12, pp. 1334-1339.
	A47 Giembycz, M.A., Phosphodiesterase 4 Inhibitors and the Treatment of Asthma, Drugs 2000 Feb; 59(2), pp. 193-212.
	A48 Gonzaga, R.A.F. et al., The Lancet, 3/30/85, p. 751.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

SERIAL NO.

09/938,160

CASE NO.

P-191

FILING DATE

AUGUST 23, 2001

GROUP ART UNIT

NOT YET ASSIGNED

APPLICANT(S): WHITEHEAD ET AL.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A49	5,602,171	2/11/97	Tang et al.		
	A50	5,614,530	3/25/97	Kumar et al.		
	A51	5,614,627	3/25/97	Takase et al.		
	A52	5,708,022	1/13/98	Bastos et al.		
	A53	5,776,752	7/7/98	Beavo et al.		
	A54	5,789,553	8/4/98	Beavo et al.		
	A55	5,798,374	8/25/98	Tang et al.		
	A56	5,800,987	9/1/98	Beavo et al.		
	A57	5,852,035	12/22/98	Pamukcu et al.		
	A58	5,858,694	1/12/99	Piazza et al.		
	A59	5,861,396	1/19/99	Niewöhner et al.		
	A60	5,874,440	2/23/99	Pamukcu et al.		
	A61	5,883,110	3/16/99	Tang et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
	A62	EP 0 722 944 A1	1/8/96	EPO	→ US 5,861,404	
	A63	EP 1 074 258 A3	4/18/01	EPO	→ US 2002 0119974 A1	
	A64	GB 807,826	1/21/59	United Kingdom		
	A65	GB 2 063 249 A	6/3/81	United Kingdom		
	A66	HEI 8-311035	11/26/96	Japan		

EXAMINER
INITIAL

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	A67	Hammermann, R. et al., Phosphodiesterase Inhibitors and Forskolin Up-regulate Arginase Activity in Rabbit Alveolar Macrophages, Pulmonary Pharmacology and Therapeutics 2000; Vol. 13, No. 3, pp. 141-147.
	A68	He W. et al., Novel Cyclic Compounds as Potent Phosphodiesterase 4 Inhibitors, J. Med. Chem., Vol. 41, Part 22, pp. 4216-4223 (Oct 22 1998).
	A69	Hollander AP et al., Expression of hypoxia-inducible factor 1 alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint, Arthritis Rheum. 2001 Jul; 44(7): 1540-4 (Abstract Only).
	A70	Imahashi K. et al., Type IV Phosphodiesterase Inhibitor Suppresses Insulin-Dependent Myocardial Glucose Uptake, Clin Exp Pharmacol Physiol 2001 Apr; 28(4), pp. 290-291 (Abstract Only).
	A71	Ishikawa O. et al., Macrophage infiltration in the skin of patients with systemic sclerosis, J. Rheumatology 1992 Aug; 19(8), pp. 1202-1206 (Abstract Only).
	A72	Kapur S. et al., Expression of Nitric Oxide Synthase in Skeletal Muscle, Diabetes, Vol. 46, Nov. 1997, pp. 1691-1700.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

SERIAL NO.

09/938,160

CASE NO.

P-191

FILING DATE

AUGUST 23, 2001

GROUP ART UNIT

NOT YET ASSIGNED

APPLICANT(S): WHITEHEAD ET AL.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A73	5,885,834	3/23/99	Epstein		
	A74	5,902,827	5/11/99	Pamukcu et al.		
	A75	5,922,595	7/13/99	Fisher et al.		
	A76	5,942,520	8/24/99	Pamukcu et al.		
	A77	5,948,911	9/7/99	Pamukcu et al.		
	A78	5,958,982	9/28/99	Pamukcu et al.		
	A79	5,990,117	11/23/99	Pamukcu et al.		
	A80	5,998,463	12/7/99	Hulin et al.		
	A81	6,008,215	12/28/99	Flockerzi		
	A82	6,015,677	1/18/00	Beavo et al.		
	A83	6,034,099	3/7/00	Pamukcu et al.		
	A84	6,037,345	3/14/00	Pamukcu et al.		
	A85	6,046,199	4/4/00	Pamukcu et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES	NO
	A86	SHO 61-106521	5/24/86	Japan			
	A87	WO 01/04099 A1	1/18/01	PCT			
	A88	WO 00/12501	3/9/00	PCT	→ US	6,436,952	
	A89	WO 00/26201	5/11/00	PCT	→ US	6,376,493	
	A90	WO 00/23091	4/27/00	PCT			

EXAMINER
INITIAL

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	A91	Kelly J. et al., Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors, British Journal of Pharmacology (1998) 124, PP. 129-140.
	A92	Kelly J. et al., Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [³ H]R(-)-rolipram binding by selective inhibitors, Biochem. J. (1996) 318, pp. 425-436.
	A93	Kumar A. et al., Analgesic and anti-inflammatory effects of phosphodiesterase inhibitors, Indian J Exp Biol 2000 Jan;38(1), pp. 26-30 (Abstract Only)
	A94	Lee MS et al., A comparative immunohistochemical study of lichen planus and discoid lupus erythematosus, Australas J. Dermatol. 1996 Nov.; 37(4): 188-92 (Abstract Only).
	A95	McPherson M.A. et al., A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein, FEBS Letters 464 (1999), pp. 48-52.
	A96	Mery P.F. et al., Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes, Mol. Pharmacology 1995 Jul;48(1), pp. 121-130 (Abstract Only)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NOV 19 2003

Page 5 of 8

FORM PTO-1449	SERIAL NO. 09/938,760	CASE NO. P-191
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE AUGUST 23, 2001	GROUP ART UNIT NOT YET ASSIGNED
	APPLICANT(S): WHITEHEAD ET AL.	

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A97	6,046,206	4/4/00	Pamukcu et al.		
	A98	6,046,216	4/4/00	Piazza et al.		
	A99	6,060,477	5/9/00	Piazza et al.		
	A100	6,066,634	5/23/00	Sperl et al.		
	A101	6,069,240	5/30/00	Wigler et al.		
	A102	6,071,934	6/6/00	Sperl et al.		
	A103	6,077,842	6/20/00	Pamukcu et al.		
	A104	6,080,540	6/27/00	Wigler et al.		
	A105	6,080,742	6/27/00	German et al.		
	A106	6,080,772	6/27/00	Tang et al.		
	A107	6,100,025	8/8/00	Wigler et al.		
	A108	6,107,295	8/22/00	Rochus et al.		
	A109	6,124,303	9/26/00	Pamukcu et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES	NO
	A110	WO 00/26208	5/11/00	PCT			
	A111	WO 00/27861	5/18/00	PCT			
	A112	WO 00/42017	7/20/00	PCT			
	A113	WO 00/42018	7/20/00	PCT			
	A114	WO 00/42019	7/20/00	PCT			

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages; etc.)	
	A115	Méry, Pierre-François et al., EHNA as an Inhibitor of PDE2: A Pharmacological and Biochemical Study in Cardiac Myocytes, Phosphodiesterase Inhibitors (1996), pp. 81-88.
	A116	Michie, A.M. et al., Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram, Cell Signal 1996 Feb;8(2), pp. 97-110.
	A117	Niebauer J. et al., Local L-Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis, Circulation 1999;100, pp. 1830-1835.
	A118	Odoux C. et al., Endothelin-1 secretion by alveolar macrophages in systemic sclerosis, Am. J. Respir. Crit. Care Med. 1997 Nov;156(5), pp. 1429-1435 (Abstract Only).
	A119	Ostensen M. et al., Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus, Lupus (2001) 10, pp. 135-139.
	A120	Piazza G.A. et al., Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis, Cancer Research 55, Jul 15 1995, pp. 3110-3116.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NOV 1 9 2003

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(use several sheets if necessary)

SERIAL NO.

09/938,160

CASE NO.

P-191

FILING DATE

AUGUST 23, 2001

GROUP ART UNIT

NOT YET ASSIGNED

APPLICANT(S): WHITEHEAD ET AL.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A121 6,133,271	10/17/00	Pamukcu et al.		
	A122 6,143,746	11/7/00	Daugan et al.		
	A123 6,143,759	11/7/00	Flockerzi		
	A124 6,143,765	11/7/00	Tang et al.		
	A125 6,143,777	11/7/00	Jonas et al.		
	A126 6,169,090	1/2/01	Dyke et al.		
	A127 6,174,884	1/16/01	Haning et al.		
	A128 6,187,779	2/13/01	Pamukcu et al.		
	A129 6,200,771	3/13/01	Liu et al.		
	A130 6,200,980	3/13/01	Piazza et al.		
	A131 6,207,666	3/27/01	Piazza et al.		
	A132 6,211,177	4/3/01	Sperl et al.		
	A133 6,211,220	4/3/01	Pamukcu et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
	A134 WO 00/42034	7/20/00	PCT		
	A135 WO 00/59890	10/12/00	PCT		
	A136 WO 00/64424	11/2/00	PCT		
	A137 WO 99/65880	11/23/99	PCT	→ US 6,417,188	
	A138 WO 98/19679A1	5/14/98	PCT (Claims Only)		

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
	A139 Reis E. et al., Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice, PNAS 97(23): pp. 12764-12769.
	A140 Rice P.L. et al., Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites, Cancer Research 2001, Feb 15;61(4), pp. 1541-1547 (Abstract Only).
	A141 Soh, Jae-Won et al., Cyclic GMP Mediates Apoptosis Induced by Sulindac Derivatives via Activation of c-Jun NH ₂ -Terminal Kinase 1, Clinical Cancer Research Vol. 6, pp. 4136-4141, October 2000.
	A142 Soh, Jae-Won et al., Protein Kinase G Activates the JNK1 Pathway via Phosphorylation of MEKK1, The Journal of Biological Chemistry, Vol. 276, No. 19, pp. 16406-16410 (2001).
	A143 Thompson, W.J. et al., Exisulind Induction of Apoptosis Involves Guanosine 3',5'-Cyclic Monophosphate Phosphodiesterase Inhibition, Protein Kinase G Activation, and Attenuated β -Catenin, Cancer Research 60, pp. 3338-3342, July 1, 2000.
	A144 Tien, Xiao-Ying, et al., Activation of the Cystic Fibrosis Transmembrane Conductance Regulator by cGMP in the Human Colonic Cancer Cell Line, Caco-2, The Journal of Biological Chemistry, Vol. 269, No. 1, pp. 51-54 (1994).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

